Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy-Reference-Cited by-同舟云学术

Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy

Published:2019-09-16 Issue:6 Volume:84 Page:1219-1227
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Crucitta Stefania,Restante Giuliana,Del Re Marzia^ORCID,Bertolini Ilaria,Bona Eleonora,Rofi Eleonora,Fontanelli Lorenzo,Gianfilippo Giulia,Fogli Stefano,Stasi Irene,Ghilli Matteo,Fontana Andrea,Danesi Romano

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03933-z.pdf

Reference42 articles.

1. Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicines 5:2. https://doi.org/10.3390/biomedicines5020034

2. Giuliano S, Pages G (2013) Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 95(6):1110–1119. https://doi.org/10.1016/j.biochi.2013.03.002

3. Redondo A, Ramos Vazquez M, Manso L, Gil Gil MJ, Garau Llinas I, Garcia-Garre E, Rodriguez CA, Chacon JI, Lopez-Vivanco G (2018) Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. Onco Targets Ther 11:5845–5852. https://doi.org/10.2147/OTT.S170303

4. Raouf S, Bertelli G, Ograbek A, Field P, Tran I (2019) Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. Future Oncol 15(5):543–561. https://doi.org/10.2217/fon-2018-0480

5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676. https://doi.org/10.1056/NEJMoa072113

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer pharmacogenetics: a systematic review;Pharmacogenomics;2023-01

2. Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review);Molecular Medicine Reports;2022-05-25

3. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen;Technology in Cancer Research & Treatment;2021-01-01

4. Clinically relevant endothelial nitric oxide synthase polymorphisms and their impact on drug response;Expert Opinion on Drug Metabolism & Toxicology;2020-08-29

5. Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy;Cancer Science;2020-08-29